LAVAL, QC, July 3 /CNW Telbec/ - For the very first time in its history,
the Laval- based firm Algorithme Pharma, which already has many U.S. clients,
has achieved its goal of locating in the U.S., through its acquisition of a
new clinical research centre in Baltimore, Maryland.
This acquisition, which is helping Algorithme Pharma get closer to its
U.S. clientele, in order to better serve this market, is the first milestone
in its U.S. expansion plans. The Clinical Pharmacology Research Unit, owned by
Bioanalytical Systems Inc. (NASDAQ: BASI) in Baltimore, will be operating,
from now on, under the name of Algorithme Pharma USA Inc.
"This acquisition is the first step in our U.S. expansion strategy and is
part of a vast development plan to pursue our organic growth in Canada and
take advantage of business opportunities that will enable us to diversify on
the international scene, in both the U.S. and Europe", stated Louis Caillé,
President and Chief Executive Officer of Algorithme Pharma.
The activities related to the new Baltimore clinic include a
46,000-square-foot work space with 120 beds (20 of which are dedicated for
Intensive Monitoring Unit), divided into three separate research units, making
it possible to carry out a number of studies at the same time, so that
Algorithme Pharma can increase its production capacity by over 50%. BASi is a
pharmaceutical development company providing contract research services and
monitoring instruments to the world's leading drug development companies and
medical research organizations. The Clinical Pharmacology Research Unit in
Baltimore specializes in Phase I clinical trials and bioequivalence studies.
Algorithme Pharma's new clinical research centre has a core team of
approximately 40 employees who will join those already working at the
company's facilities in Montreal and Laval.
About Algorithme Pharma - As a worldwide leader in clinical research and
bioanalysis, Algorithme Pharma provides a wide range of services for
bioequivalence and early stage development (Phase I) studies to the generic,
pharmaceutical, and bio-technology industries. In addition to its multi-unit
clinical facilities (more than 250 beds) and with its new dedicated
state-of-the-art facility for Phase I clinical studies, Algorithme Pharma
offers different services including protocol designs, CTD/ICH clinical
reports, data management, biostatistics, quality assurance (QA) and regulatory
Successfully audited by US FDA, Canada's TPD, Brazil's ANVISA, France's
AFSSAPS, UK's MHRA and more recently Austria's AGES regulatory authorities,
Algorithme Pharma conducts over 250 clinical trials per year. Proud winner of
Canada's 50 Best Managed Companies, Algorithme Pharma's main success resides
in the flexibility and commitment of its 500 + dedicated and knowledgeable
employees to deliver first-class service to each Client.
For further information:
For further information: Press Relations: Ingrid Saumart, (514)
490-0206, firstname.lastname@example.org; Marius S. Brisson, President; Source: Mr.
Louis Caillé, President & CEO, Algorithme Pharma, www.algopharm.com